DOCSLIB.ORG

Supplement, Table 8. Genes Affected by Celecoxib in "Immune Response" Gene Ontology Category

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplement, Table 8. Genes Affected by Celecoxib in Supplement, Table 8. Genes affected by Celecoxib in "immune response" Gene Ontology category Geometri UniGene HUGO Parametric Gene c mean of Cluster ID Symbol p-value ratios P/F Hs.25647 FOS v-fos FBJ murine osteosarcoma viral oncogene homolog 0.621 0.0407 Hs.423 PAP pancreatitis-associated protein 0.683 0.0040 Hs.407546 TNFAIP6 tumor necrosis factor, alpha-induced protein 6 0.736 0.0053 Hs.308680 C1R complement component 1, r subcomponent 0.751 0.0179 Hs.789 CXCL1 chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) 0.762 0.0579 Hs.110675 APOE apolipoprotein E 0.762 0.0253 Hs.407506 INHA inhibin, alpha 0.764 0.0185 Hs.78065 C7 complement component 7 0.765 0.0081 Hs.134231 VPS45A vacuolar protein sorting 45A (yeast) 0.78 0.0000 Hs.436042 CXCL12 chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) 0.788 0.0189 Hs.172674 NFATC3 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 0.793 0.0019 Hs.421342 STAT3 signal transducer and activator of transcription 3 (acute-phase response factor) 0.799 0.0314 Hs.1735 INHBB inhibin, beta B (activin AB beta polypeptide) 0.801 0.0311 Hs.458355 C1S complement component 1, s subcomponent 0.815 0.0238 Hs.77546 ANKRD15 ankyrin repeat domain 15 0.818 0.0017 GALNAC4S- Hs.523379 6ST B cell RAG associated protein 0.829 0.0522 Hs.421194 TPST1 tyrosylprotein sulfotransferase 1 0.831 0.0206 Hs.7957 ADAR adenosine deaminase, RNA-specific 0.834 0.0210 Hs.374357 NFRKB nuclear factor related to kappa B binding protein 0.849 0.0104 Hs.1281 C5 complement component 5 0.859 0.0397 Hs.383913 BLM Bloom syndrome 0.866 0.0079 Hs.79107 MAPK14 mitogen-activated protein kinase 14 0.868 0.0032 Hs.2161 C5R1 complement component 5 receptor 1 (C5a ligand) 1.135 0.1185 Hs.155421 AFP alpha-fetoprotein 1.169 0.1460 Hs.180533 MAP2K3 mitogen-activated protein kinase kinase 3 1.169 0.0097 Hs.1721 IL11 interleukin 11 1.184 0.0337 Hs.88974 CYBB cytochrome b-245, beta polypeptide (chronic granulomatous disease) 1.192 0.0139 Hs.38069 C8B complement component 8, beta polypeptide 1.202 0.0228 Hs.446684 ASE-1 CD3-epsilon-associated protein; antisense to ERCC-1 1.21 0.0379 Hs.461934 SPN sialophorin (gpL115, leukosialin, CD43) 1.213 0.0112 Hs.86131 FADD Fas (TNFRSF6)-associated via death domain 1.223 0.0046 Hs.355307 TNFRSF7 tumor necrosis factor receptor superfamily, member 7 1.225 0.0194 Hs.132781 WSX1 class I cytokine receptor 1.232 0.0590 Hs.2007 TNFSF6 tumor necrosis factor (ligand) superfamily, member 6 1.234 0.0567 Hs.652 TNFSF5 tumor necrosis factor (ligand) superfamily, member 5 (hyper-IgM syndrome) 1.236 0.0091 Hs.193418 TNFRSF9 tumor necrosis factor receptor superfamily, member 9 1.24 0.0668 myxovirus (influenza virus) resistance 1, interferon-inducible protein p78 Hs.436836 MX1 (mouse) 1.248 0.0455 Hs.36972 CD7 CD7 antigen (p41) 1.249 0.0344 Hs.73917 IL4 interleukin 4 1.256 0.0551 Hs.54460 CCL11 chemokine (C-C motif) ligand 11 1.258 0.0105 Hs.82542 AOAH acyloxyacyl hydrolase (neutrophil) 1.259 0.0400 Hs.458485 G1P2 interferon, alpha-inducible protein (clone IFI-15K) 1.261 0.0061 Hs.442787 ZNF148 zinc finger protein 148 (pHZ-52) 1.267 0.0101 Hs.1570 HRH1 histamine receptor H1 1.267 0.0097 Hs.87205 LY64 lymphocyte antigen 64 homolog, radioprotective 105kDa (mouse) 1.268 0.0167 Hs.1162 HLA-DMB major histocompatibility complex, class II, DM beta 1.28 0.0174 Hs.81564 PF4 platelet factor 4 (chemokine (C-X-C motif) ligand 4) 1.282 0.0071 Hs.1285 C8G complement component 8, gamma polypeptide 1.282 0.0041 Hs.251526 CCL7 chemokine (C-C motif) ligand 7 1.285 0.0589 Hs.193400 IL6R interleukin 6 receptor 1.292 0.0015 Hs.174312 TLR4 toll-like receptor 4 1.293 0.0161 Hs.387871 TNFSF10 tumor necrosis factor (ligand) superfamily, member 10 1.293 0.0300 Hs.66742 CCL17 chemokine (C-C motif) ligand 17 1.296 0.0402 Hs.159553 CMKLR1 chemokine-like receptor 1 1.296 0.0140 Hs.72933 PF4V1 platelet factor 4 variant 1 1.297 0.0227 Hs.89499 ALOX5 arachidonate 5-lipoxygenase 1.298 0.0263 Hs.76364 AIF1 allograft inflammatory factor 1 1.298 0.0082 Hs.1416 FCER2 Fc fragment of IgE, low affinity II, receptor for (CD23A) 1.299 0.0138 Hs.85258 CD8A CD8 antigen, alpha polypeptide (p32) 1.302 0.0844 Hs.90708 GZMA granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3) 1.307 0.0129 Hs.103527 SH2D2A SH2 domain protein 2A 1.308 0.0396 Hs.442936 OAS1 2',5'-oligoadenylate synthetase 1, 40/46kDa 1.318 0.0128 Hs.54517 FCN2 ficolin (collagen/fibrinogen domain containing lectin) 2 (hucolin) 1.319 0.0959 leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM Hs.67846 LILRB4 domains), member 4 1.324 0.0446 Hs.440898 FCN1 ficolin (collagen/fibrinogen domain containing) 1 1.325 0.0202 Hs.266175 PAG phosphoprotein associated with glycosphingolipid-enriched microdomains 1.327 0.0028 Hs.2605 CMRF35 CMRF35 leukocyte immunoglobulin-like receptor 1.327 0.0389 Hs.512682 CEACAM1 carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) 1.34 0.0095 Hs.99886 C4BPB complement component 4 binding protein, beta 1.34 0.0019 proteasome (prosome, macropain) subunit, beta type, 9 (large multifunctional Hs.381081 PSMB9 protease 2) 1.35 0.0004 Hs.153563 LY75 lymphocyte antigen 75 1.354 0.0228 Hs.105806 GNLY granulysin 1.365 0.0001 Hs.14453 ICSBP1 interferon consensus sequence binding protein 1 1.376 0.0088 immunoglobulin J polypeptide, linker protein for immunoglobulin alpha and mu Hs.381568 IGJ polypeptides 1.38 0.0239 Hs.234569 ZAP70 zeta-chain (TCR) associated protein kinase 70kDa 1.386 0.0009 Hs.417628 CRHR1 corticotropin releasing hormone receptor 1 1.389 0.0129 Hs.1310 CD1B CD1B antigen, b polypeptide 1.392 0.0101 Hs.334846 PVRL1 poliovirus receptor-related 1 (herpesvirus entry mediator C; nectin) 1.394 0.0033 Hs.76415 ITIH4 inter-alpha (globulin) inhibitor H4 (plasma Kallikrein-sensitive glycoprotein) 1.399 0.0165 Hs.518546 CCRL2 chemokine (C-C motif) receptor-like 2 1.4 0.0181 Hs.93210 C8A complement component 8, alpha polypeptide 1.405 0.0174 Hs.116481 CD72 CD72 antigen 1.418 0.0226 Hs.194778 IL8RA interleukin 8 receptor, alpha 1.419 0.0030 Hs.515605 KIR2DL4 killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 4 1.422 0.0082 Hs.14155 ICOSL inducible T-cell co-stimulator ligand 1.447 0.0003 Hs.501452 EBI3 Epstein-Barr virus induced gene 3 1.464 0.0270 Hs.2259 CD3G CD3G antigen, gamma polypeptide (TiT3 complex) 1.466 0.0053 Hs.405667 CD8B1 CD8 antigen, beta polypeptide 1 (p37) 1.466 0.0060 Hs.423190 CRIP1 cysteine-rich protein 1 (intestinal) 1.472 0.0121 Hs.3003 CD3E CD3E antigen, epsilon polypeptide (TiT3 complex) 1.474 0.0057 Hs.89679 IL2 interleukin 2 1.49 0.0292 Hs.211575 IFNA2 interferon, alpha 2 1.498 0.0023 Hs.93177 IFNB1 interferon, beta 1, fibroblast 1.513 0.0224 Hs.32949 DEFB1 defensin, beta 1 1.523 0.0022 Hs.1311 CD1C CD1C antigen, c polypeptide 1.527 0.0264 Hs.840 INDO indoleamine-pyrrole 2,3 dioxygenase 1.613 0.0172 Hs.151544 SH2D1A SH2 domain protein 1A, Duncan's disease (lymphoproliferative syndrome) 1.683 0.0260 Hs.376208 LTB lymphotoxin beta (TNF superfamily, member 3) 1.719 0.0043 Hs.95327 CD3D CD3D antigen, delta polypeptide (TiT3 complex) 1.743 0.0038 Hs.164021 CXCL6 chemokine (C-X-C motif) ligand 6 (granulocyte chemotactic protein 2) 1.769 0.0000 Hs.502 TAP2 transporter 2, ATP-binding cassette, sub-family B (MDR/TAP) 1.812 0.0062 Hs.438040 MS4A1 membrane-spanning 4-domains, subfamily A, member 1 1.814 0.0313 Hs.135194 IGSF6 immunoglobulin superfamily, member 6 1.964 0.0000.
Load more

Recommended publications
  • ENSG Gene Encodes Effector TCR Pathway Costimulation Inhibitory/Exhaustion Synapse/Adhesion Chemokines/Receptors
    ENSG Gene Encodes Effector TCR pathway Costimulation Inhibitory/exhaustion Synapse/adhesion Chemokines/receptors ENSG00000111537 IFNG IFNg x ENSG00000109471 IL2 IL-2 x ENSG00000232810 TNF TNFa x ENSG00000271503 CCL5 CCL5 x x ENSG00000139187 KLRG1 Klrg1 x ENSG00000117560 FASLG Fas ligand x ENSG00000121858 TNFSF10 TRAIL x ENSG00000134545 KLRC1 Klrc1 / NKG2A x ENSG00000213809 KLRK1 Klrk1 / NKG2D x ENSG00000188389 PDCD1 PD-1 x x ENSG00000117281 CD160 CD160 x x ENSG00000134460 IL2RA IL-2 receptor x subunit alpha ENSG00000110324 IL10RA IL-10 receptor x subunit alpha ENSG00000115604 IL18R1 IL-18 receptor 1 x ENSG00000115607 IL18RAP IL-18 receptor x accessory protein ENSG00000081985 IL12RB2 IL-12 receptor x beta 2 ENSG00000186810 CXCR3 CXCR3 x x ENSG00000005844 ITGAL CD11a x ENSG00000160255 ITGB2 CD18; Integrin x x beta-2 ENSG00000156886 ITGAD CD11d x ENSG00000140678 ITGAX; CD11c x x Integrin alpha-X ENSG00000115232 ITGA4 CD49d; Integrin x x alpha-4 ENSG00000169896 ITGAM CD11b; Integrin x x alpha-M ENSG00000138378 STAT4 Stat4 x ENSG00000115415 STAT1 Stat1 x ENSG00000170581 STAT2 Stat2 x ENSG00000126561 STAT5a Stat5a x ENSG00000162434 JAK1 Jak1 x ENSG00000100453 GZMB Granzyme B x ENSG00000145649 GZMA Granzyme A x ENSG00000180644 PRF1 Perforin 1 x ENSG00000115523 GNLY Granulysin x ENSG00000100450 GZMH Granzyme H x ENSG00000113088 GZMK Granzyme K x ENSG00000057657 PRDM1 Blimp-1 x ENSG00000073861 TBX21 T-bet x ENSG00000115738 ID2 ID2 x ENSG00000176083 ZNF683 Hobit x ENSG00000137265 IRF4 Interferon x regulatory factor 4 ENSG00000140968 IRF8 Interferon
    [Show full text]
  • Screening and Identification of Key Biomarkers in Clear Cell Renal Cell Carcinoma Based on Bioinformatics Analysis
    bioRxiv preprint doi: https://doi.org/10.1101/2020.12.21.423889; this version posted December 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Screening and identification of key biomarkers in clear cell renal cell carcinoma based on bioinformatics analysis Basavaraj Vastrad1, Chanabasayya Vastrad*2 , Iranna Kotturshetti 1. Department of Biochemistry, Basaveshwar College of Pharmacy, Gadag, Karnataka 582103, India. 2. Biostatistics and Bioinformatics, Chanabasava Nilaya, Bharthinagar, Dharwad 580001, Karanataka, India. 3. Department of Ayurveda, Rajiv Gandhi Education Society`s Ayurvedic Medical College, Ron, Karnataka 562209, India. * Chanabasayya Vastrad [email protected] Ph: +919480073398 Chanabasava Nilaya, Bharthinagar, Dharwad 580001 , Karanataka, India bioRxiv preprint doi: https://doi.org/10.1101/2020.12.21.423889; this version posted December 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Clear cell renal cell carcinoma (ccRCC) is one of the most common types of malignancy of the urinary system. The pathogenesis and effective diagnosis of ccRCC have become popular topics for research in the previous decade. In the current study, an integrated bioinformatics analysis was performed to identify core genes associated in ccRCC. An expression dataset (GSE105261) was downloaded from the Gene Expression Omnibus database, and included 26 ccRCC and 9 normal kideny samples. Assessment of the microarray dataset led to the recognition of differentially expressed genes (DEGs), which was subsequently used for pathway and gene ontology (GO) enrichment analysis.
    [Show full text]
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse
    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
    [Show full text]
  • SUPPLEMENTARY DATA Supplementary Tables Table S1
    1 SUPPLEMENTARY DATA 2 3 Supplementary Tables 4 Table S1. Gene signatures Gene signature Genes Cytolytic GNLY, KLRK1, KLRB1, GZMH, GZMA, KLRD1, NKG7 Cytotoxic CD8+ T cells CD8A, GZMA, GZMB, IFNG, EOMES, PRF1 Activated CD4+ T cells CD4, IL2RA, CD69 CD4+ Treg cells FOXP3, CTLA4, ICOS Immune checkpoints—T cells BTLA, LAG3, HAVCR2, PDCD1, TIGIT, CTLA4 T cells CD2, CD3D, CD3E, CD3G, CD6, TRAT1, CD28, LCK B cells CD79A, MS4A1, CD19, STAP1, KIAA0125, POU2AF1, FCRL5 NK cells SLAMF7, KLRC3, KLRK1, KLRC2, KLRD1 Monocytes CD14, CD16, CD163, CSF1R, HLA-DR LAPTM5, LAIR1, CD4, CSF1R, CD163, ADAP2, CD68, MRC1, M2 macrophages PTPRC, SLA, SEPSECS, MSR1, FPR3, FCGR2A, FCGR3A, IDO1, RERE, ABL2, CD163L1, STAT3, SBNO2, CSF1, CSF2 FAP, FN1, MMP2, BGN, LOXL2, PDPN, PDGFRB, COL12a1, Active fibroblasts COL5A1, COL8A2, THY1, PALLD Antigen processing TAPBP, TAP1, TAP2, PSMB9, PSMB8 Immune checkpoints—APC CD274, PDCD1LG2, IDO1 Costimulatory ligands CD40, CD80, CD86, CD70, TNFRSF18 CD27, CD28, ICOS, TNFRSF4, TNFRSF14, TNFRSF18, Costimulatory receptors TNFSF14, CD226 Myeloid inflammation CCL2, IL1B, CXCL8, IL6, PTGS2 1 DERL1, DERL2, DNAJB11, DNAJB9, DNAJC10, DNAJC3, ER stress EDEM1, EDEM2, EDEM3, EIF2AK3, ERO1L, HERPUD1, PDIA3, PDIA6, SEC61A1, SERP1, SYVN1 RRM2, UBE2C, BIRC5, CEP55, CCNB1, NUF2, NDC80, Proliferation MKI67, CDC20, TYMS 5 ER, endoplasmic reticulum; NK, natural killer. 6 7 2 8 Table S2. Most common all-cause and treatment-related AEs Patients (N = 45) All cause Treatment related Eventa Any grade Grade 3/4 Any grade Grade 3/4 Any AE 45 (100.0) 20 (44.4)
    [Show full text]
  • Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model
    Downloaded from http://www.jimmunol.org/ by guest on September 25, 2021 T + is online at: average * The Journal of Immunology , 34 of which you can access for free at: 2016; 197:1477-1488; Prepublished online 1 July from submission to initial decision 4 weeks from acceptance to publication 2016; doi: 10.4049/jimmunol.1600589 http://www.jimmunol.org/content/197/4/1477 Molecular Profile of Tumor-Specific CD8 Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A. Waugh, Sonia M. Leach, Brandon L. Moore, Tullia C. Bruno, Jonathan D. Buhrman and Jill E. Slansky J Immunol cites 95 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2016/07/01/jimmunol.160058 9.DCSupplemental This article http://www.jimmunol.org/content/197/4/1477.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 25, 2021. The Journal of Immunology Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A.
    [Show full text]
  • How Macrophages Deal with Death
    REVIEWS CELL DEATH AND IMMUNITY How macrophages deal with death Greg Lemke Abstract | Tissue macrophages rapidly recognize and engulf apoptotic cells. These events require the display of so- called eat-me signals on the apoptotic cell surface, the most fundamental of which is phosphatidylserine (PtdSer). Externalization of this phospholipid is catalysed by scramblase enzymes, several of which are activated by caspase cleavage. PtdSer is detected both by macrophage receptors that bind to this phospholipid directly and by receptors that bind to a soluble bridging protein that is independently bound to PtdSer. Prominent among the latter receptors are the MER and AXL receptor tyrosine kinases. Eat-me signals also trigger macrophages to engulf virus- infected or metabolically traumatized, but still living, cells, and this ‘murder by phagocytosis’ may be a common phenomenon. Finally , the localized presentation of PtdSer and other eat- me signals on delimited cell surface domains may enable the phagocytic pruning of these ‘locally dead’ domains by macrophages, most notably by microglia of the central nervous system. In long- lived organisms, abundant cell types are often process. Efferocytosis is a remarkably efficient business: short- lived. In the human body, for example, the macrophages can engulf apoptotic cells in less than lifespan of many white blood cells — including neutro- 10 minutes, and it is therefore difficult experimentally to phils, eosinophils and platelets — is less than 2 weeks. detect free apoptotic cells in vivo, even in tissues where For normal healthy humans, a direct consequence of large numbers are generated7. Many of the molecules this turnover is the routine generation of more than that macrophages and other phagocytes use to recognize 100 billion dead cells each and every day of life1,2.
    [Show full text]
  • WO 2016/147053 Al 22 September 2016 (22.09.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/147053 Al 22 September 2016 (22.09.2016) P O P C T (51) International Patent Classification: (71) Applicant: RESVERLOGIX CORP. [CA/CA]; 300, A61K 31/551 (2006.01) A61P 37/02 (2006.01) 4820 Richard Road Sw, Calgary, AB, T3E 6L1 (CA). A61K 31/517 (2006.01) C07D 239/91 (2006.01) (72) Inventors: WASIAK, Sylwia; 431 Whispering Water (21) International Application Number: Trail, Calgary, AB, T3Z 3V1 (CA). KULIKOWSKI, PCT/IB20 16/000443 Ewelina, B.; 31100 Swift Creek Terrace, Calgary, AB, T3Z 0B7 (CA). HALLIDAY, Christopher, R.A.; 403 (22) International Filing Date: 138-18th Avenue SE, Calgary, AB, T2G 5P9 (CA). GIL- 10 March 2016 (10.03.2016) HAM, Dean; 249 Scenic View Close NW, Calgary, AB, (25) Filing Language: English T3L 1Y5 (CA). (26) Publication Language: English (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (30) Priority Data: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, 62/132,572 13 March 2015 (13.03.2015) US BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, 62/264,768 8 December 2015 (08. 12.2015) US DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, [Continued on nextpage] (54) Title: COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF COMPLEMENT-ASSOCIATED DISEASES (57) Abstract: The invention comprises methods of modulating the complement cascade in a mammal and for treating and/or preventing diseases and disorders as sociated with the complement pathway by administering a compound of Formula I or Formula II, such as, for example, 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)- 5,7-dimethoxyquinazolin-4(3H)-one or a pharmaceutically acceptable salt thereof.
    [Show full text]
  • Phyre 2 Results for A1YIY0
    Email [email protected] Description A1YIY0 Tue Jul 30 13:19:15 BST Date 2013 Unique Job 1035bc4b501530df ID Detailed template information # Template Alignment Coverage 3D Model Confidence % i.d. Template Information PDB header:cell adhesion Chain: A: PDB Molecule:down syndrome cell adhesion molecule 1 c3dmkA_ Alignment 100.0 14 (dscam) isoform PDBTitle: crystal structure of down syndrome cell adhesion molecule (dscam)2 isoform 1.30.30, n-terminal eight ig domains PDB header:cell adhesion 2 c2om5A_ Alignment 100.0 20 Chain: A: PDB Molecule:contactin 2; PDBTitle: n-terminal fragment of human tax1 PDB header:cell adhesion 3 c3jxaA_ Alignment 100.0 21 Chain: A: PDB Molecule:contactin 4; PDBTitle: immunoglobulin domains 1-4 of mouse cntn4 PDB header:signaling protein/transferase Chain: A: PDB Molecule:tek tyrosine kinase variant; 4 c4k0vA_ 100.0 12 Alignment PDBTitle: structural basis for angiopoietin-1 mediated signaling initiation PDB header:immune system Chain: A: PDB Molecule:natural cytotoxicity triggering receptor 1; 5 c1p6fA_ 100.0 9 Alignment PDBTitle: structure of the human natural cytotoxicity receptor nkp46 PDB header:immune system/receptor 6 c1ollA_ Alignment 99.9 9 Chain: A: PDB Molecule:nk receptor; PDBTitle: extracellular region of the human receptor nkp46 PDB header:viral protein Chain: A: PDB Molecule:hoc head outer capsid protein; 7 c3shsA_ 99.9 18 Alignment PDBTitle: three n-terminal domains of the bacteriophage rb49 highly immunogenic2 outer capsid protein (hoc) PDB header:immune system Chain: E: PDB Molecule:natural
    [Show full text]
  • BD Biosciences New RUO Reagents - November 2020
    BD Biosciences New RUO reagents - November 2020 Reactivity Description Format Clone Size Cat. number Hu CD133 FITC W6B3C1 100µg 567029 Hu CD133 FITC W6B3C1 25µg 567033 Hu CD39 PE A1/CD39 100Tst 567156 Hu CD39 PE A1/CD39 25Tst 567157 Hu KIR2DL1/S1/S3/S5 PE HP-MA4 100Tst 567158 Hu KIR2DL1/S1/S3/S5 PE HP-MA4 25Tst 567159 Hu IL-22 Alexa Fluor® 647 MH22B2 100µg 567160 Hu IL-22 Alexa Fluor® 647 MH22B2 25µg 567161 Hu CD99 R718 TU12 50µg 751651 Hu CD161 R718 DX12 50µg 751652 Hu CD116 R718 HGMCSFR-M1 50µg 751653 Hu HLA-G R718 87G 50µg 751670 Hu CD27 R718 O323 50µg 751686 Hu CD80 (B7-1) R718 2D10.4 50µg 751737 Hu Integrin αvβ5 R718 ALULA 50µg 751738 Hu CD266 (Tweak-R) R718 ITEM-4 50µg 751739 Hu ErbB3 (HER-3) R718 SGP1 50µg 751799 Hu TCR Vβ5.1 R718 LC4 50µg 751816 Hu CD123 (IL-3Ra) R718 6H6 50µg 751844 Hu CD1a R718 SK9 50µg 751847 Hu CD20 R718 L27 50µg 751849 Hu Disial GD2 R718 14.G2A 50µg 751851 Reactivity Description Format Clone Size Cat. number Hu CD71 R718 L01.1 50µg 751853 Hu CD278 (ICOS) R718 DX29 50µg 751854 Hu B7-H4 R718 MIH43 50µg 751857 Hu CD53 R718 HI29 50µg 751858 Hu CD197 (CCR7) R718 2-L1-A 50µg 751859 Hu CD197 (CCR7) R718 3D12 50µg 751861 Hu CD31 R718 L133.1 50µg 751863 Hu EGF Receptor R718 EMAB-134 50µg 751864 Hu CD8b R718 2ST8.5H7 50µg 751867 Hu CD31 R718 MBC 78.2 50µg 751869 Hu CD162 R718 KPL-1 50µg 751873 Hu CD24 R718 ML5 50µg 751874 Hu CD159C (NKG2C) R718 134591 50µg 751876 Hu CD169 (Siglec-1) R718 7-239 50µg 751877 Hu CD16b R718 CLB-GRAN11.5 50µg 751880 Hu IgM R718 UCH-B1 50µg 751881 Hu CD275 R718 2D3/B7-H2 50µg 751883 Hu CD307e
    [Show full text]
  • CD226 T Cells Expressing the Receptors TIGIT and Divergent Phenotypes of Human Regulatory
    The Journal of Immunology Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226 Christopher A. Fuhrman,*,1 Wen-I Yeh,*,1 Howard R. Seay,* Priya Saikumar Lakshmi,* Gaurav Chopra,† Lin Zhang,* Daniel J. Perry,* Stephanie A. McClymont,† Mahesh Yadav,† Maria-Cecilia Lopez,‡ Henry V. Baker,‡ Ying Zhang,x Yizheng Li,{ Maryann Whitley,{ David von Schack,x Mark A. Atkinson,* Jeffrey A. Bluestone,‡ and Todd M. Brusko* Regulatory T cells (Tregs) play a central role in counteracting inflammation and autoimmunity. A more complete understanding of cellular heterogeneity and the potential for lineage plasticity in human Treg subsets may identify markers of disease pathogenesis and facilitate the development of optimized cellular therapeutics. To better elucidate human Treg subsets, we conducted direct transcriptional profiling of CD4+FOXP3+Helios+ thymic-derived Tregs and CD4+FOXP3+Helios2 T cells, followed by comparison with CD4+FOXP32Helios2 T conventional cells. These analyses revealed that the coinhibitory receptor T cell Ig and ITIM domain (TIGIT) was highly expressed on thymic-derived Tregs. TIGIT and the costimulatory factor CD226 bind the common ligand CD155. Thus, we analyzed the cellular distribution and suppressive activity of isolated subsets of CD4+CD25+CD127lo/2 T cells expressing CD226 and/or TIGIT. We observed TIGIT is highly expressed and upregulated on Tregs after activation and in vitro expansion, and is associated with lineage stability and suppressive capacity. Conversely, the CD226+TIGIT2 population was associated with reduced Treg purity and suppressive capacity after expansion, along with a marked increase in IL-10 and effector cytokine production. These studies provide additional markers to delineate functionally distinct Treg subsets that may help direct cellular therapies and provide important phenotypic markers for assessing the role of Tregs in health and disease.
    [Show full text]
  • Complement Component 4 Genes Contribute Sex-Specific Vulnerability in Diverse Illnesses
    bioRxiv preprint doi: https://doi.org/10.1101/761718; this version posted September 9, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Complement component 4 genes contribute sex-specific vulnerability in diverse illnesses Nolan Kamitaki1,2, Aswin Sekar1,2, Robert E. Handsaker1,2, Heather de Rivera1,2, Katherine Tooley1,2, David L. Morris3, Kimberly E. Taylor4, Christopher W. Whelan1,2, Philip Tombleson3, Loes M. Olde Loohuis5,6, Schizophrenia Working Group of the Psychiatric Genomics Consortium7, Michael Boehnke8, Robert P. Kimberly9, Kenneth M. Kaufman10, John B. Harley10, Carl D. Langefeld11, Christine E. Seidman1,12,13, Michele T. Pato14, Carlos N. Pato14, Roel A. Ophoff5,6, Robert R. Graham15, Lindsey A. Criswell4, Timothy J. Vyse3, Steven A. McCarroll1,2 1 Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA 2 Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA 3 Department of Medical and Molecular Genetics, King’s College London, London WC2R 2LS, UK 4 Rosalind Russell / Ephraim P Engleman Rheumatology Research Center, Division of Rheumatology, UCSF School of Medicine, San Francisco, California 94143, USA 5 Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, California 90095, USA 6 Center for Neurobehavioral Genetics, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, California 90095, USA 7 A full list of collaborators is in Supplementary Information.
    [Show full text]
  • Investigation of Candidate Genes and Mechanisms Underlying Obesity
    Prashanth et al. BMC Endocrine Disorders (2021) 21:80 https://doi.org/10.1186/s12902-021-00718-5 RESEARCH ARTICLE Open Access Investigation of candidate genes and mechanisms underlying obesity associated type 2 diabetes mellitus using bioinformatics analysis and screening of small drug molecules G. Prashanth1 , Basavaraj Vastrad2 , Anandkumar Tengli3 , Chanabasayya Vastrad4* and Iranna Kotturshetti5 Abstract Background: Obesity associated type 2 diabetes mellitus is a metabolic disorder ; however, the etiology of obesity associated type 2 diabetes mellitus remains largely unknown. There is an urgent need to further broaden the understanding of the molecular mechanism associated in obesity associated type 2 diabetes mellitus. Methods: To screen the differentially expressed genes (DEGs) that might play essential roles in obesity associated type 2 diabetes mellitus, the publicly available expression profiling by high throughput sequencing data (GSE143319) was downloaded and screened for DEGs. Then, Gene Ontology (GO) and REACTOME pathway enrichment analysis were performed. The protein - protein interaction network, miRNA - target genes regulatory network and TF-target gene regulatory network were constructed and analyzed for identification of hub and target genes. The hub genes were validated by receiver operating characteristic (ROC) curve analysis and RT- PCR analysis. Finally, a molecular docking study was performed on over expressed proteins to predict the target small drug molecules. Results: A total of 820 DEGs were identified between
    [Show full text]